Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - adenosine 3 mg/ml;  ;   - solution for injection - 6 mg/2ml - active: adenosine 3 mg/ml     excipient: sodium chloride water for injection - therapeutic indications rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white syndrome). diagnostic indications aid to diagnosis of broad or narrow qrs complex supraventricular tachycardias. although adenosine-claris 6 mg/2 ml is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. sensitisation of intra-cavitary electrophysiological investigations.

Canada - Engels - Health Canada

mylan pharmaceuticals ulc - adenosine - solution - 3mg - adenosine 3mg - class iv antiarrythmics

Verenigde Staten - Engels - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - intravenous adenosine injection is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine injection administration. it is important to be sure the adenosine injection solution actually reaches the systemic circulation (see dosage & administration. adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. intravenous adenosine injection is contraindicated in: second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker). known hypersensitivity to adenosine.

Jordanië - Engels - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية المنار - manar drug store - adenosine 3 mg - 3 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - intravenous adenosine injection is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine injection solution actually reaches the systemic circulation (see dosage and administration). adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. intravenous adenosine injection is contraindicated in: 1. second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). 2. sinus node disease, such as sick sinus syndrome or sym

Verenigde Staten - Engels - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - intravenous adenosine injection is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine injection administration. it is important to be sure the adenosine injection solution actually reaches the systemic circulation (see dosage and administration). adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration. intravenous adenosine injection is contraindicated in: second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). sinus node disease, such as sick sinus syndrome or

Canada - Engels - Health Canada

fujisawa pharmaceutical co, division of fujisawa canada inc. - adenosine - liquid - 3mg - adenosine 3mg - miscellaneous cardiac drugs

Canada - Engels - Health Canada

fujisawa pharmaceutical co, division of fujisawa canada inc. - adenosine - liquid - 3mg - adenosine 3mg - miscellaneous cardiac drugs

Verenigde Staten - Engels - NLM (National Library of Medicine)

agila specialties private limited - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml

Verenigde Staten - Engels - NLM (National Library of Medicine)

astellas pharma us, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenocard (adenosine injection) is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenocard administration. it is important to be sure the adenocard solution actually reaches the systemic circulation (see dosage and administration). adenocard does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenocard administration. intravenous adenocard (adenosine injection) is contraindicated in: